Gevo, Inc. (NASDAQ:GEVO) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.62% to 0.35 with around 4.81 Million shares have changed hands in this session. Magellan Midstream Partners, L.P. (MMP) and LBC Tank Terminals, LLC announced that they have entered into a letter of intent for Seabrook Logistics, LLC, owned 50/50 by Magellan and LBC, to expand its crude oil and condensate storage, marine capacity and pipeline infrastructure in the Houston Gulf Coast area.
As contemplated by the letter of intent, Seabrook Logistics proposes to construct up to 4 million barrels (636,000 cubic meters) of additional storage for a total of nearly 5 million barrels (795,000 cubic meters) adjacent to LBC’s existing terminal in Seabrook, Texas. The stock is going forward its fifty-two week low with 59.09% and lagging behind from its 52-week high price with -91.97%.
Likewise the positive performance for the quarter recorded as -10.26% and for the year was -88.71%, while the YTD performance remained at -43.55%. GEVO has Average True Range for 14 days of 0.05.
Magellan Midstream Partners LP (NYSE:MMP) [Trend Analysis] retains strong position in active trade, as shares scoring 0.79% to $70.05 in a active trade session, while looking at the shares volume, around 1.09 Million shares have changed hands in this session. Cellectar Biosciences, Inc. (CLRB) announced that United States Patent and Trademark Office has issued U.S. Patent No. 9,339,564, which covers the treatment of cancer stem cells employing the company’s phospholipid drug conjugate delivery platform technology; specifically, either of the company’s current PDC products, CLR 131 or CLR 125, in combination with external beam radiation. This patent, which provides intellectual property protection to at least June 2030, is based on one of multiple patent applications directed to the treatment of cancer stem cells. The firm has institutional ownership of 62.90%, while insider ownership included 0.30%. MMP attains analyst recommendation of 2.10 with week’s performance of -1.63%. Investors looking further ahead will note that the Price to next year’s EPS is 8.51%.
Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) [Trend Analysis] swings enthusiastically in regular trading session, it a gain of 7.62% to close at $3.25. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that positive preliminary results from an ongoing proof-of-concept study of evinacumab (REGN1500) in patients with Homozygous Familial Hypercholestrolemia (HoFH) were presented at the 84th European Atherosclerosis Society (EAS) Congress in Innsbruck, Austria.
The interim data from the first 4 patients treated in this study showed that evinacumab added to current lipid-lowering therapy reduced low-density lipoprotein cholesterol (LDL-C) levels by an additional 55 percent (mean reduction; range 25 to 90 percent) at week 4 compared to baseline. Evinacumab is an investigational monoclonal antibody to angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 acts as an inhibitor of lipoprotein lipase and endothelial lipase, and appears to play a central role in lipoprotein metabolism. LRB is going forward its fifty-two week low with 225.00% and lagging behind from its 52-week high price with -91.65%. CLRB last month stock price volatility remained 28.32%.